The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality

Introduction: The COVID-19 pandemic reflects liver damage. A study carried out in China (Guan WJ et al. N Engl J Med. 2020) reported that in more than 21% of cases there was an elevation of liver enzymes (ELE), with only 2.1% of them having previous liver disease. ELE is frequent in anticoagulated p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerezo Manchado, Juan Jose, Olivera, Pável E, Lopez Abellan, María Dolores, Campoy Castaño, Desiree, Velasquez, César A, Rodriguez Rojas, Carlos, Ramos Arenas, Veronica, Flores, Katia, Cárdenas Gámez, Rubén, García de Guadiana Romualdo, Luis, Iturbe Hernandez, Teodoro, Sierra, Jorge, Salinas, Ramón
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
332.Anticoagulation and Antithrombotic Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330343/
http://dx.doi.org/10.1182/blood-2020-142451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330343/
http://dx.doi.org/10.1182/blood-2020-142451

Ejemplares similares